| Expression pattern: |
UP |
| Associated gene: |
ENO2, AGO2 |
| Associated microRNA: |
miR‐665 |
| Biological function: |
promotes proliferation and migration; promotes metastasis/invasive abilities; promotes tumor growth in vivo |
| Molecular mechanism: |
ceRNA sponge mechanism: circESYT2 sponges miR-665 to upregulate ENO2; AGO2-dependent RISC involvement |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Wound Healing Assay; Transwell Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Clinical Sample Validation; Cohort Study; Survival Analysis |
| Clinical significance: |
High circESYT2 (hsa_circ_002142) expression is associated with high histological grade and worse prognosis (disadvantage in disease-free survival) in the Huashan cohort; correlated with tumor size and tumor thrombus |
| Description: |
circESYT2 (hsa_circ_002142), derived from ESYT2, is up-regulated in HCC and mainly localized in the cytoplasm. It promotes HCC cell proliferation, migration and metastasis in vitro and in cell line-derived xenograft models by acting as a ceRNA that sponges miR-665, thereby increasing ENO2 expression; high circESYT2 is associated with worse patient prognosis. |
| Confidence score: |
0.8905 |